Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

ClinicalTrials.gov ID: NCT02974621

Public ClinicalTrials.gov record NCT02974621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Study identification

NCT ID
NCT02974621
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
70 participants

Conditions and interventions

Interventions

  • Bevacizumab Biological
  • Cediranib Drug
  • Cediranib Maleate Drug
  • Olaparib Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 6, 2017
Primary completion
Dec 30, 2022
Completion
Jul 16, 2026
Last update posted
Jul 6, 2026

2017 – 2026

United States locations

U.S. sites
27
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
UC San Diego Moores Cancer Center La Jolla California 92093
UCHealth University of Colorado Hospital Aurora Colorado 80045
Smilow Cancer Hospital-Derby Care Center Derby Connecticut 06418
Smilow Cancer Hospital Care Center-Fairfield Fairfield Connecticut 06824
Smilow Cancer Hospital Care Center - Guilford Guilford Connecticut 06437
Smilow Cancer Hospital Care Center at Saint Francis Hartford Connecticut 06105
Smilow Cancer Center/Yale-New Haven Hospital New Haven Connecticut 06510
Yale University New Haven Connecticut 06520
Smilow Cancer Hospital-Orange Care Center Orange Connecticut 06477
Smilow Cancer Hospital-Torrington Care Center Torrington Connecticut 06790
Smilow Cancer Hospital Care Center-Trumbull Trumbull Connecticut 06611
Smilow Cancer Hospital-Waterbury Care Center Waterbury Connecticut 06708
Smilow Cancer Hospital Care Center - Waterford Waterford Connecticut 06385
Moffitt Cancer Center Tampa Florida 33612
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Dana-Farber Cancer Institute Boston Massachusetts 02215
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters Missouri 63376
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141
Washington University School of Medicine St Louis Missouri 63110
Siteman Cancer Center-South County St Louis Missouri 63129
Siteman Cancer Center at Christian Hospital St Louis Missouri 63136
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032
Duke University Medical Center Durham North Carolina 27710
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02974621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02974621 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →